William Hait - Feb 14, 2022 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
Officer
Signature
Raavi Deol, as attorney-in-fact for William Hait
Stock symbol
JNJ
Transactions as of
Feb 14, 2022
Transactions value $
$4,901,552
Form type
4
Date filed
2/18/2022, 06:15 PM
Previous filing
Feb 18, 2022
Next filing
Apr 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $0 +8.13K +10.66% $0.00 84.4K Feb 15, 2022 Direct F1
transaction JNJ Common Stock Tax liability -$690K -4.16K -4.93% $165.89 80.2K Feb 15, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Employee Stock Options (Right to Buy) Award $5.59M +33.7K $165.89 33.7K Feb 14, 2022 Common Stock 33.7K Direct F3
transaction JNJ Restricted Share Units Award $0 +3.41K $0.00 3.41K Feb 14, 2022 Common Stock 3.41K Direct F4
transaction JNJ Performance Share Units Options Exercise $0 -8.13K -91.3% $0.00 775 Feb 15, 2022 Common Stock 8.13K Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting.
F2 Shares withheld for payment of taxes upon vesting of Performance Share Units.
F3 Awarded under Issuer's Long-Term Incentive Plan.
F4 Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant.
F5 Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019. A portion of these Performance Share Units have been forfeited.

Remarks:

Title: Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer